Skip to main content

Table 2 Characteristics of patients enrolled in CVOTs referred to in the text

From: Current perspectives on cardiovascular outcome trials in diabetes

  Age Diabetes type HbA1c levels Cardiovascular status Prior antihyperglycemic treatment BMI (kg/m2)
SAVOR-TIMI53 ≥40 T2DM ≥6.5 % CVD OR high CV risk AHA 31.1
EXAMINE ≥18 T2DM (6.5, 11.0 %) ACS (15, 90) days before AHA 28.7
TECOS ≥50 T2DM (6.5, 11.0 %) preexisting CVD AHA 30.2
ELIXA ≥30 T2DM ≥7.0 % ACS min. 180 days before AHA 30.2
EMPA-REG OUTCOME ≥18 T2DM (7.0, 10.0 %) Preexisting CVD Drug näive OR AHA ≤45
LEADER ≥50 T2DM ≥7.0 % Preexisting CVD/cerebrovascular disease/vascular disease/renalORheart failure at ≥50 OR CV risk at ≥60 Drug näive OR AHA 32.5
SUSTAIN-6 ≥50 T2DM ≥7.0 % Preexisting CVD at ≥50 OR preCVD at ≥60 Drug näive OR AHA 31.1
EXSCEL ≥18 T2DM (7.0, 10.0 %)   Specific AHA  
CAROLINA ≥40 ≤85 T2DM (6.5, 7.5–8.5 %) CVD OR specified diabetes end-organ damage OR age ≥70 years OR ≥2 specified CV risk factors   ≤45
REWIND ≥50 T2DM ≤9.5 % Preexisting vascular disease OR ≥CV risk factors AHA  
ITCA650 ≥40 T2DM ≥6.5 % Preexisting coronary, cerebrovascular or peripheral artery disease   
DECLARE-TIMI ≥40 T2DM   High risk CV events   
CARMELINA ≥18 T2DM (6.5, 10.0 %) High risk CV events Drug näive OR specific AHA ≤45
DEVOTE ≥50 T2DM ≤7.0 % CVD OR renal disease OR ≥60 CV risk Specific AHA  
MK-3102 ≥40 T2DM (6.5, 10.0 %) Preexisting vascular disease   
Ertugliflozin trial ≥40 T2DM (7.0, 10.5 %) Preexisting vascular disease Drug näive OR AHA ≥18
TOSCA-IT ≥50 ≤75 T2DM (7.0, 9.0 %)   Specific AHA 20–45
CANVAS ≥40 T2DM (7.0, 10.5 %) Preexisting CVD OR high CV risk Drug näive OR AHA  
  1. AHA anti-hyperglycemic agents